Esperion Therapeutics, Inc. (ESPR) was reiterated a ‘Sell’ by Chardan Capital Markets analysts on Wednesday. The broker also lowered its price target on the stock to $50 from $55. Esperion Therapeutics, Inc. shares have a PEG and P/B ratio of 1.99 and 7.18, respectively. EPS is ($2.26). Currently there are 8 analysts that rate ESPR […]
View the full post at: Notable Downgrades: Esperion Therapeutics (ESPR), Alibaba Group (BABA), American Airlines (AAL), Nvidia (NVDA)